XML 53 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Share-based Compensation (Tables)
9 Months Ended
Mar. 31, 2022
Share-based Compensation  
Schedule of weighted average assumptions

Nine Months Ended

March 31, 2021

Risk-free interest rate

0.2

%

Expected volatility

82.5

%

Expected dividend yield

%

Forfeiture rate

%

Expected term

5.0

years

Weighted average fair value

$

3.86

Summary of stock option award activity

    

    

    

    

    

Weighted

Weighted-

Average

Average

Aggregate

Remaining

Exercise

Intrinsic

Contractual

(In thousands, except for weighted average price and life data)

    

Awards

    

Price

    

Value

    

Life (yrs.)

Outstanding at June 30, 2021

 

1,046

9.51

$

25

7.2

Exercised

 

(3)

3.55

$

2

Forfeited, expired or repurchased

 

(96)

15.24

Outstanding at March 31, 2022

 

947

8.95

$

6.6

Vested and expected to vest at March 31, 2022

 

947

8.95

$

6.6

Exercisable at March 31, 2022

 

542

10.95

$

5.8

Summary of non-vested restricted stock awards

Weighted

Average Grant -

Aggregate

(In thousands, except for weighted average price data)

    

Awards

    

date Fair Value

    

Intrinsic Value

Non-vested at June 30, 2021

 

1,350

$

6.75

Granted

 

1,110

 

4.14

Vested

 

(1,000)

 

5.97

$

3,788

Forfeited

 

(90)

 

5.66

Non-vested at March 31, 2022

 

1,370

$

5.28

Schedule of non-vested performance-based shares

Weighted

Average Grant -

(In thousands, except for weighted average price and life data)

    

Awards

    

date Fair Value

    

Non-vested at June 30, 2021

 

531

$

10.29

Granted

 

617

$

6.04

Performance adjustment (1)

(40)

$

17.69

Vested

 

(58)

$

7.72

Non-vested at March 31, 2022

 

1,050

$

7.65

(1)Represents the adjustment based on the performance of the July 2018 awards, which was below the Threshold goal level at the end of the three-year performance period.
Schedule of allocation of share-based compensation

Three Months Ended

Nine Months Ended

March 31, 

March 31, 

(In thousands)

    

2022

    

2021

    

2022

    

2021

Selling, general and administrative expenses

$

1,501

$

1,411

$

6,313

$

5,632

Research and development expenses

 

29

 

132

 

151

 

419

Cost of sales

 

169

 

320

 

562

 

1,145

Total

$

1,699

$

1,863

$

7,026

$

7,196

Tax benefit at statutory rate

$

382

$

419

$

1,581

$

1,619